Cosmos Health (NASDAQ:COSM – Get Free Report) and BeOne Medicines (NASDAQ:ONC – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Cosmos Health and BeOne Medicines, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cosmos Health | 1 | 0 | 0 | 0 | 1.00 |
| BeOne Medicines | 1 | 1 | 13 | 0 | 2.80 |
BeOne Medicines has a consensus target price of $378.43, indicating a potential upside of 12.57%. Given BeOne Medicines’ stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Cosmos Health.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cosmos Health | $54.43 million | 0.35 | -$16.18 million | ($0.75) | -0.67 |
| BeOne Medicines | $3.81 billion | 9.67 | -$644.79 million | $0.51 | 659.14 |
Cosmos Health has higher earnings, but lower revenue than BeOne Medicines. Cosmos Health is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cosmos Health and BeOne Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cosmos Health | -31.01% | -33.19% | -13.65% |
| BeOne Medicines | 1.38% | 5.52% | 3.17% |
Volatility and Risk
Cosmos Health has a beta of 5.37, indicating that its stock price is 437% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.
Insider and Institutional Ownership
12.6% of Cosmos Health shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 25.1% of Cosmos Health shares are owned by insiders. Comparatively, 6.6% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
BeOne Medicines beats Cosmos Health on 11 of the 14 factors compared between the two stocks.
About Cosmos Health
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors. It sells its products through independent wholesale distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Receive News & Ratings for Cosmos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmos Health and related companies with MarketBeat.com's FREE daily email newsletter.
